Aytu BioScience, Inc. (NASDAQ:AYTU) is expected to report first quarter earnings results, after market close, on Thursday 12th November 2020.
Analysts polled by Thomson Reuters anticipate first quarter loss of $ 0.05 per share.
Looking ahead, the full year loss are expected at $ 0.19 per share on the revenues of $ 59.01 million.
Previous Quarter Performance
Aytu BioScience, Inc. unwinded loss for the fourth quarter of $ 0.02 per share, from the revenue of $ 14.86 million. The quarterly revenues improved 763.95 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.03 per share from $ 11.24 million in revenue. The bottom line results beat street analysts by $ 0.01 or 33.33 percent, at the same time, top line results outshined analysts by $ 3.62 million or 32.21 percent.
Stock Performance
Shares of Aytu BioScience, Inc. traded up $ 0.01 or 0.99 percent on Wednesday, reaching $ 1.02 with volume of 1.45 million shares. Aytu BioScience, Inc. has traded high as $ 1.02 and has cracked $ 0.99 on the downward trend
The closing price of $ 1.02, representing a 197.06 % increase from the 52 week low of $ 0.34 and a 66.22 % decrease over the 52 week high of $ 2.99.
The company has a market capital of $ 128.35 million and is part of the Healthcare sector and Biotechnology industry.
Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen.
